Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

GT Biopharma Inc (GTBP)

GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference GlobeNewswire - Tue Feb 17, 6:30AM CST

SAN FRANCISCO, CALIFORNIA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics...

GTBP : 0.4561 (-6.61%)
Medicine labratory by gorodenkoff via iStock
GT Biopharma Submits IND for Solid Tumor Immunotherapy Targeting Portion of $362 Billion Market as Cash Position Nearly Triples Barchart Impact - Sun Feb 8, 8:53AM CST

GT Biopharma announced it has submitted an IND to the FDA for GTB-5550, its third NK cell engager entering clinical development for B7-H3–expressing solid tumors, while reporting a strengthen

GTBP : 0.4561 (-6.61%)
3D rendering of a NK Cell (Natural Killer Cell) destroying a cancer cell by Alpha Tauri 3D Graphics via Shutterstock
GT Biopharma (GTBP) Gets FDA Green Light to Test New Cancer-Fighting Tech in Humans Barchart Impact - Wed Feb 4, 9:03AM CST

GT Biopharma (GTBP) received FDA clearance to begin human trials of its TriKE®-based cancer therapy GTB-5550, marking a strategic expansion from blood cancers into the much larger solid tumor market by...

GTBP : 0.4561 (-6.61%)
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3 GlobeNewswire - Tue Feb 3, 7:30AM CST

GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known to express B7-H3 Unaudited proforma cash balance as of January...

GTBP : 0.4561 (-6.61%)
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers GlobeNewswire - Thu Jan 15, 7:30AM CST

GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extend...

GTBP : 0.4561 (-6.61%)
Breakthrough ASH Data Drives Blood Cancer Market To $240B Valuation BayStreet.ca - Thu Dec 11, 2025

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – The 2025 American Society of Hematology meeting showcased pivotal advances in blood cancer treatment, with...

PTGX : 83.09 (+0.12%)
KPTI : 9.67 (+4.54%)
GTBP : 0.4561 (-6.61%)
GSK : 60.85 (-0.54%)
TAK : 18.66 (+0.65%)
Novel Immunotherapy Breakthroughs Advance Blood Cancer Treatment BayStreet.ca - Thu Dec 4, 2025

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists have engineered breakthrough cell therapies that can be mass-produced and stored ready-to-use, addressing...

ZLAB : 20.08 (-0.50%)
GTBP : 0.4561 (-6.61%)
ROIV : 27.52 (+0.15%)
CCCC : 2.1200 (+10.99%)
BMY : 60.30 (+0.95%)
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire - Fri Nov 14, 2025

Phase 1 trial evaluating GTB-3650 TriKE ® for relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to actively enroll with the next update anticipated in Q1 2026...

GTBP : 0.4561 (-6.61%)
Targeted Cell Therapies and Precision Degraders Drive $404B Cancer Market Expansion BayStreet.ca - Thu Oct 23, 2025

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists engineered invisible immune cells in October 2025 that hide from rejection while destroying tumors[1],...

IOVA : 2.85 (+4.78%)
GMAB : 28.90 (-0.89%)
NRIX : 15.79 (+2.00%)
GTBP : 0.4561 (-6.61%)
SLS : 4.04 (+6.60%)
Biomarker-Driven Therapies And AI Technologies Transform $312B Precision Oncology Market BayStreet.ca - Fri Oct 17, 2025

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Biomarker-driven approaches enhance the likelihood of identifying optimal patient populations and streamline...

CORT : 34.24 (-14.01%)
ARAY : 0.5523 (+3.33%)
KURA : 8.58 (+1.06%)
GTBP : 0.4561 (-6.61%)
TNGX : 12.35 (-0.48%)

Barchart Exclusives

Kraft Heinz Pauses Its Breakup Plans. Should You Buy the High-Yield Dividend Stock Here? Barchart - Thu Feb 19, 6:30PM CST
Kraft Heinz is still facing many tough challenges. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot